Drug Database
Back to search

Finland· FI-REL-REL62791

AMGEVITA

A adalimumab product containing adalimumab, registered in Finland by Amgen Europe B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC L04AB04

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedAMGEVITAATCL04AB04REGISTER NO.FI-REL-REL62791PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about adalimumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Adalimumab is registered in 14 of 19 countries.

Countries holding a registration under ATC L04AB04 (adalimumab), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 9 of them publish a price we can compare per daily dose
Search adalimumab products by name

Adalimumab · ATC L04AB04

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of adalimumab costs, country by country.

Normalised to the WHO defined daily dose (2.9 mg), the median price runs from $0.015 in France to $36.00 in Switzerland — a ×2384 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Adalimumab · price per daily dose (2.9 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$36.00
  • FR France$0.015
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Fimea (Finland)
Active substance
Adalimumab
Manufacturer
Amgen Europe B.V.
Country
Finland (FI)
ATC code
L04AB04
ATC class
Adalimumab
Defined daily dose
2.9 mg, P
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 1

1 priced
  • fi_myyntilupa
    558599
    0.2 ml
    EUR 118.86

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

429 interactions on record for adalimumab.

Graded by severity as the source publishes them — 286 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check adalimumab against other medicinesHow interaction checks work

Adalimumab · interactions on record

429 records

  • 286 severe
  • 136 moderate
  • 7 minor

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Adalimumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All adalimumab products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Hukyndra, Humira
  • Iceland · Amgevita, Amsparity
  • Liechtenstein · Amsparity, Hefiya
  • Norway · Amgevita, Amsparity

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/3f017df1-3c1a-469c-bd0e-099de96c6f8e
GET /v1/drugs/3f017df1-3c1a-469c-bd0e-099de96c6f8e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "2.9",
  "form": "injektioneste, liuos, esitäytetty ruisku",
  "route": "Ihon alle",
  "ddd_unit": "mg",
  "strength": "20 mg",
  "atc_label": "adalimumabi",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/16/1164/010",
  "fimea_rel_id": "REL62791",
  "authorised_at": "2024-05-16"
}
API referenceMCP serverPlans

See everything about adalimumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console